ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative
RNS Number : 6718V MaxCyte, Inc. 09 July 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Change of Name of Nominated Adviser and Broker ROCKVILLE, MD , July 9, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 8834U MaxCyte, Inc. 03 July 2024 TR-1: N otification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting
RNS Number : 8115U MaxCyte, Inc. 02 July 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , July 2, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
RNS Number : 6980U MaxCyte, Inc. 02 July 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, MD , July 2, 2024 : MaxCyte Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 2055U MaxCyte, Inc. 27 June 2024 Publication of Annual Report ROCKVILLE, MD , June 27, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and
RNS Number : 4058S MaxCyte, Inc. 14 June 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options and Restricted Stock Units ROCKVILLE, MD , June 14, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 0511S MaxCyte, Inc. 12 June 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Results of AGM Rockville, Maryland - June 12 , 2024: MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 9400R MaxCyte, Inc. 11 June 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") PDMR Dealing ROCKVILLE, MD , June 12, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery,
RNS Number : 9173Q MaxCyte, Inc. 03 June 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights and Block Listing Return ROCKVILLE, MD , June 3, 2024 : MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
